Charles River Laboratories Intl. Inc vs Twilio Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $302.66 (market cap $14.23B), while Twilio Inc trades at $289.05 (market cap $42.35B). The key difference: Twilio Inc is far larger — about 3× Charles River Laboratories Intl. Inc's market cap, and Twilio Inc is more actively traded (1,862,642 versus 1,176,885). Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Twilio Inc for 56 Days on average.
| CRL | TWLO | |
|---|---|---|
Market Cap | $14.23B | $42.35B |
Volume | 1,176,885 | 1,862,642 |
Sector | Health | Technology |
52-Week High | $310.77 | $301.27 |
52-Week Low | $149.93 | $106.23 |
Typical Hold Time | 33 Days | 56 Days |
Enterprise Value | $17.06B | $40.76B |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $300.53, up 0.08% on the day, with a bullish technical outlook and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, though it faces profitability challenges with a negative net income margin and ROE. Recent investor day presentations highlighted a strategic plan targeting 5-7% revenue growth and $300 million in savings by 2030, driving positive sentiment.
The outlook is cautiously optimistic, supported by analyst buy ratings and a $305.50 consensus price target, but risks include ongoing margin pressure, volatile non-human primate costs, and a high valuation multiple. Earnings growth and successful execution of the new strategic plan are critical for sustained upside.
Twilio (TWLO) trades at $289.18, up 5.93% in the past 24 hours, with a bullish technical signal and strong earnings beats in recent quarters. The company's revenue growth accelerated to $5.07 billion in 2025, with net income turning positive at $33.83 million, and is projected to reach $1.1 billion in 2026. Recent inclusion in the S&P 500 index and positive analyst sentiment with 76.92% buy ratings highlight investor confidence, though high valuation multiples like a P/E of 38.09 and EV/EBITDA of 81.63 suggest premium pricing.
The outlook for Twilio is positive, driven by robust revenue growth, expanding profitability, and strategic positioning in AI-driven communications. Key risks include elevated valuation metrics that may limit upside, competitive pressures, and potential volatility from market reactions to earnings. Institutional interest remains strong, but investors should weigh growth prospects against current premium valuations.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Twilio Inc. is a cloud-based communication platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces, or APIs, and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
Read more on TWLO →